Fintel reports that ARK Investment Management has filed a 13G/A form with the SEC disclosing ownership of 6.70MM shares of Twist Bioscience Corp (TWST). This represents 11.85% of the company.
In their previous filing dated June 9, 2022 they reported 6.27MM shares and 11.14% of the company, an increase in shares of 6.91% and an increase in total ownership of 0.71% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 43.16% Upside
As of February 9, 2023, the average one-year price target for Twist Bioscience is $35.32. The forecasts range from a low of $29.29 to a high of $45.15. The average price target represents an increase of 43.16% from its latest reported closing price of $24.67.
The projected annual revenue for Twist Bioscience is $271MM, an increase of 25.57%. The projected annual EPS is -$4.78.
What is the Fund Sentiment?
There are 492 funds or institutions reporting positions in Twist Bioscience. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to TWST is 0.26%, a decrease of 2.54%. Total shares owned by institutions decreased in the last three months by 3.39% to 71,504K shares. The put/call ratio of TWST is 1.19, indicating a bearish outlook.
What are large shareholders doing?
ARKK - ARK Innovation ETF holds 3,965K shares representing 6.97% ownership of the company. In it's prior filing, the firm reported owning 4,090K shares, representing a decrease of 3.14%. The firm decreased its portfolio allocation in TWST by 11.45% over the last quarter.
Jpmorgan Chase & holds 3,269K shares representing 5.75% ownership of the company. In it's prior filing, the firm reported owning 3,204K shares, representing an increase of 1.98%. The firm increased its portfolio allocation in TWST by 6.01% over the last quarter.
Sumitomo Mitsui Trust Holdings holds 2,934K shares representing 5.16% ownership of the company. In it's prior filing, the firm reported owning 2,820K shares, representing an increase of 3.89%. The firm decreased its portfolio allocation in TWST by 32.89% over the last quarter.
Nikko Asset Management Americas holds 2,820K shares representing 4.96% ownership of the company. In it's prior filing, the firm reported owning 2,677K shares, representing an increase of 5.06%. The firm increased its portfolio allocation in TWST by 12.64% over the last quarter.
ARKG - ARK Genomic Revolution ETF holds 2,352K shares representing 4.14% ownership of the company. In it's prior filing, the firm reported owning 2,605K shares, representing a decrease of 10.75%. The firm decreased its portfolio allocation in TWST by 20.08% over the last quarter.
Twist Bioscience Background Information
(This description is provided by the company.)
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
